NCT04782128View on ClinicalTrials.gov

Evaluation of RC28-E Injection in Diabetic Retinopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

July 31, 2024

Conditions
Diabetic Retinopathy
Interventions
BIOLOGICAL

RC28-E injection

a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF

Trial Locations (1)

100730

Beijing Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY